An initial pharmacokinetic study with a Metered Dose Transdermal System® for delivery of the progestogen Nestorone® as a possible future contraceptive

Contraception

Volumn 76, Issue 6, 2007, Pages 432-438

  Fraser, Ian S ^a,b   Weisberg, Edith ^a,b   Kumar, Narender ^c   Kumar, Sushma ^c   Humberstone, Andrew J ^d   McCrossin, Louise ^d   Shaw, Deborah ^e   Tsong, Y Y ^c   Sitruk Ware, Regine ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FAMILY PLANNING NSW   (Australia)

^c POPULATION COUNCIL   (United States)

^d Acrux Limited   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Hormonal contraception; Nestorone; Pharmacokinetics; Transdermal delivery

Indexed keywords

ELCOMETRINE;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST TENDERNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG HALF LIFE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; NORMAL HUMAN; OVULATION INHIBITION; POSTMENOPAUSE; RADIOIMMUNOASSAY; SKIN IRRITATION;

ADMINISTRATION, CUTANEOUS; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; MIDDLE AGED; NORPROGESTERONES; POSTMENOPAUSE;

EID: 36549090122     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.08.006     Document Type: Article

References (17)

1. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 7 (2004) 347-356
2. Urdl W., Apter D., Alperstein A., et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 121 (2005) 202-210
3. Kumar N., Koide S.S., Tsong Y.Y., and Sundaram K. Nestorone®: a progestin with a unique pharmacological profile. Steroids 65 (2000) 629-636
4. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 12 (2006) 169-178
5. Sitruk-Ware R., Small M., Kumar N., Tsong Y.Y., Sundaram K., and Jackanicz T. Nestorone: clinical applications for contraception and HRT. Steroids 68 (2003) 907-913
6. Brache V., Mishell D.R., Lahteenmaki P., et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception 63 (2001) 257-261
7. Fraser I.S., Weisberg E., Brache V., et al. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception 72 (2005) 40-45
8. Croxatto H.B., and Zepeda A. Transdermal contraceptive systems: innovative technology for the twenty-first century. In: Sitruk-Ware R., and Bardin W. (Eds). Contraception. Newer pharmacological agents, devices, and delivery systems (1992), Marcel Dekker, New York 101-115
9. Diaz S., Schiappacasse V., Pavez M., et al. Clinical trial with Nestorone™ subdermal contraceptive implants. Contraception 51 (1995) 33-38
10. Humberstone A.J., Evans A.M., Nation R.L., and MacLennan A.H. Comparison of pharmacokinetics and tolerability following application of an Estraderm® 50 patch or a novel Estradiol Metered-Dose Transdermal Spray (MDTS®). Presented as the North American Menopause Society 13th Annual Meeting. Chicago, IL, US (2002)
11. Humberstone A.J., Evans A.M., and Davis S.R. A comparative study of the pharmacokinetics of testosterone (T) following administration of a Metered-Dose Transdermal Spray (MDTS) to the abdomen or forearm in healthy postmenopausal women with low serum testosterone. Presented at the Endocrine Society's 85th Annual Meeting, Philadelphia, PA, USA (2003)
12. Brache V., Massai R., Mishell Jr. D.R., et al. Ovarian function during use of Nestorone® subdermal implants. Contraception 61 (2000) 199-204
13. Olsen C.T. Evaluation of the dermal irritancy of chemicals. In: Hobson D.W. (Ed). Dermal and ocular toxicology fundamentals and methods (1991), CRC Press, Boca Raton, FL 130-131
14. Lahteenmaki P., Weiner E., Lahteenmaki P., et al. Contraception with subcutaneous capsules containing ST-1435 (Nestorone); pituitary and ovarian function and plasma levels of ST-1435. Contraception 23 (1981) 63-75
15. Heikinheimo O., Noe G., Haukkamaa M., and Lahteenmaki P. The progestin ST-1435 - rapid metabolism in women. Contraception 50 (1994) 275-289
16. Wiseman L.R., and McTavish D. Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. Drugs Aging 4 (1994) 238-256
17. Abrams L.S., Skee D.M., Natarajan J., et al. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception 64 (2001) 287-294